ライフサイエンスコーパス: lobular carcinoma

1 , since only 10% of all cancers are invasive lobular carcinoma).

2 1 patients with invasive cancer had invasive lobular carcinoma.

3 at 30, 48, and 60 months-including two with lobular carcinoma.

4 The technique is not recommended for lobular carcinoma.

5 ctal carcinoma, and ER-positive infiltrating lobular carcinoma.

6 inoma, and one had mixed invasive ductal and lobular carcinoma.

7 om this cohort, we studied SLN from cases of lobular carcinoma.

8 es, using any technique, to evaluate SLN for lobular carcinoma.

9 several 2-5-mm foci of invasive tubular and lobular carcinoma.

10 the incidence of DCIS or invasive ductal or lobular carcinoma.

11 e in the progression to the invasive form of lobular carcinoma.

12 proportionately high percentage are invasive lobular carcinoma.

13 vealed 35 ductal carcinomas and two invasive lobular carcinomas.

14 might also participate in the development of lobular carcinomas.

15 tal carcinoma (IDC) (0.2-8.9 cm), 3.5 cm for lobular carcinoma (1.6-8.0 cm), and 5.7 cm for phyllodes

16 carcinoma, 1 high-grade mammary carcinoma, 3 lobular carcinoma, 1 invasive papilloma, and 4 sentinel

17 ltrating ductal carcinoma, 29%; infiltrating lobular carcinoma, 27%; other, 9%).

18 invasive ductal carcinoma; and 12, invasive lobular carcinoma (a large percentage [33%], since only

19 (95% CI, 1.7-4.3) increased risk of invasive lobular carcinoma, a 1.5-fold (95% CI, 1.1-2.0) increase

20 tients yielded 3 carcinomas: an infiltrating lobular carcinoma, a ductal carcinoma in situ, and an in

21 Twist expression is correlated with invasive lobular carcinoma, a highly infiltrating tumor type asso

22 are the predominant appearances of invasive lobular carcinoma, and a computer-aided detection system

23 invasive ductal carcinoma, two had invasive lobular carcinoma, and one had mixed invasive ductal and

24 and intraductal carcinomas, two infiltrating lobular carcinomas, and two foci of DCIS.

25 n D1 protein in the majority of the invasive lobular carcinoma cells in 80% of the tumors.

26 Invasive lobular carcinoma comprises approximately 10% of human m

27 erative discovery of predefined factors (eg, lobular carcinoma) could trigger addition of external be

28 c classification into non-invasive ductal or lobular carcinoma (DCIS) and invasive carcinoma (ILC or

29 ER-positive infiltrating lobular carcinoma differed from ER-positive infiltrating

30 ases versus 10 of 29 (34%) cases of invasive lobular carcinoma (ILC) (P < .001) and 21 of 38 (55%) ca

31 Invasive lobular carcinoma (ILC) accounts for 8%-14% of all breas

32 Invasive lobular carcinoma (ILC) accounts for approximately 10% t

33 Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the two major histological t

34 Invasive lobular carcinoma (ILC) demonstrates lower conspicuity o

35 llelic mutations, pathognomonic for invasive lobular carcinoma (ILC) in breast neoplasms, as ground t

36 Invasive lobular carcinoma (ILC) is a histologic subtype of breas

37 Invasive lobular carcinoma (ILC) is a histological subtype of bre

38 Because invasive lobular carcinoma (ILC) is less conspicuous than invasiv

39 Invasive lobular carcinoma (ILC) is the second most common breast

40 Invasive lobular carcinoma (ILC) is the second most common type o

41 Invasive lobular carcinoma (ILC) is the second most frequently oc

42 Invasive lobular carcinoma (ILC) is the second most prevalent his

43 invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) of the breast, the most common h

44 e ductal carcinoma (IDC) or classic invasive lobular carcinoma (ILC) who were randomly assigned onto

45 Accurate staging of invasive lobular carcinoma (ILC), a subtype of breast cancer, is

46 invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC).

47 ade 3; and one grade 2 ER/PR+ HER2- invasive lobular carcinoma (ILC).

48 However, invasive lobular carcinomas (ILC) comprise up to 15% of newly dia

49 biased by small sample size, by interpreting lobular carcinoma in situ (LCIS) as a positive result, b

50 east cancer risk conferred by a diagnosis of lobular carcinoma in situ (LCIS) is poorly understood.

51 tu (DCIS) and 282 women with a first primary lobular carcinoma in situ (LCIS) were followed for contr

52 red the association between risk factors and lobular carcinoma in situ (LCIS; n = 186) with that of r

53 in the atypical lobular hyperplasia (n = 2), lobular carcinoma in situ (n = 5), or radial scar (n = 3

54 Excisional findings included lobular carcinoma in situ (n=2), ductal carcinoma in sit

55 ith breast IEN (atypical ductal hyperplasia, lobular carcinoma in situ [LCIS], or hormone-sensitive o

56 ith proliferative breast lesions (ductal and lobular carcinoma in situ and atypical ductal hyperplasi

57 oman was found to have ductal cancer and one lobular carcinoma in situ at time of CDR.

58 two, atypical lobular hyperplasia and focal lobular carcinoma in situ in one, and ductal hyperplasia

59 ical type (p=0.03), with a relative risk for lobular carcinoma in situ of 2.82 (1.72-4.63) and 1.56 (

60 ecent year of diagnosis, and the presence of lobular carcinoma in situ were significantly associated

61 nly rare cells of the noninvasive component (lobular carcinoma in situ) in the same tissue sections s

62 ar invasion (LVI), and 8% lobular neoplasia (lobular carcinoma in situ).

63 ts (one atypical lobular hyperplasia and one lobular carcinoma in situ).

64 s atypical ductal or lobular hyperplasia and lobular carcinoma in situ).

65 diotherapy, ductal carcinoma with concurrent lobular carcinoma in situ, and DCIS in elderly people an

66 h-risk lesions (atypical ductal hyperplasia, lobular carcinoma in situ, atypical lobular hyperplasia)

67 ++ were classified as being within ductal or lobular carcinoma in situ, invasive carcinoma, carcinoma

68 l hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, or radial scar) was identifie

69 ost in the vast majority (13/17) of cases of lobular carcinoma in situ, which is defined by cellular

70 equivalent measure) or women diagnosed with lobular carcinoma in situ.

71 f breast cancer,ductal carcinoma in situ, or lobular carcinoma in situ.

72 perplasia, atypical lobular hyperplasia, and lobular carcinoma in situ.

73 gn, 47 showed atypical histology, and 4 were lobular carcinoma in situ.

74 % of preinvasive lesions, such as ductal and lobular carcinoma in situ.

75 eight atypical lobular hyperplasia, and one lobular carcinoma in situ.

76 or atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ w

77 nfiltrating ductal carcinoma or infiltrating lobular carcinoma in the breast or axillary lymph nodes)

78 ive breast cancer (IBC) after a diagnosis of lobular carcinoma-in-situ (LCIS) by using Surveillance,

79 Women who have either lobular carcinoma-in-situ or atypical ductal or lobular

80 pical hyperplasia, Gail risk greater than 5, lobular carcinoma-in-situ, or two or more first-degree r

81 Metastatic lobular carcinoma is difficult to identify in SLN becaus

82 Lobular carcinoma is less common than ductal carcinoma b

83 ase presents a clinical challenge given that lobular carcinoma is more difficult to detect than ducta

84 ed to biopsy-proved diagnosis of 94 invasive lobular carcinoma lesions.

85 rrectly marked a high percentage of invasive lobular carcinoma lesions.

86 Mixed invasive ductal and lobular carcinoma (MDLC) is a rare histologic subtype of

87 Agreement on lobular carcinoma metastasis classification improved fro

88 nd molecular features of metastatic invasive lobular carcinoma (mILC) and metastatic invasive ductal

89 ion, we orthotopically transplanted invasive lobular carcinoma (mILC) fragments into mammary glands o

90 invasive ductal carcinoma (n = 51), invasive lobular carcinoma (n = 5), or ductal carcinoma in situ (

91 186) with that of risk factors and invasive lobular carcinomas (n = 1,191).

92 frequently amplified and highly expressed in lobular carcinomas of the breast.

93 was more likely to show malignancy, invasive lobular carcinoma, or ductal carcinoma in situ alone (P

94 IS (P for heterogeneity = 0.03) and invasive lobular carcinomas (P for heterogeneity < 0.01).

95 ations generally were similar for ductal and lobular carcinomas (P-heterogeneity=0.43) and by tumor s

96 Invasive lobular carcinoma, postsurgical size>20mm, and p53<15% w

97 ed essentially constant from 1987-1999 while lobular carcinoma rates increased steadily.

98 % CI, 1.3-5.3] increases in risk of invasive lobular carcinoma, respectively.

99 conclude that the vast majority of invasive lobular carcinomas show overexpression of cyclin D1 prot

100 comprises 27 indisputable cases of invasive lobular carcinoma showing varying degrees of cytological

101 d in cell lines derived from mouse and human lobular carcinomas that possess high FGFR1 activity.

102 s a critical component of FGFR1 signaling in lobular carcinomas, thus implicating RSK as a candidate

103 cyclin D1 protein overexpression in invasive lobular carcinoma, to investigate the cause of the prote

104 patients with stages I-IV invasive ductal or lobular carcinoma treated at an academic medical center

105 ozole is greater for patients diagnosed with lobular carcinoma versus ductal carcinoma.

106 entified for the intraoperative detection of lobular carcinoma versus ductal carcinoma.

107 was significantly increased in patients with lobular carcinoma vs those with ductal carcinoma (adjust

108 Risk of invasive ductal or lobular carcinoma was associated with current use (< or

109 was excluded as a positive result, invasive lobular carcinoma was not significantly more bilateral t

110 oplasms may be broadly divided into invasive lobular carcinoma, well-differentiated subtypes of invas

111 Sixty-one cases of pure invasive lobular carcinoma were identified.

112 Two (18%) of 11 foci of infiltrating lobular carcinoma were missed at both US and mammography

113 mplete loss, as exemplified by E-cadherin in lobular carcinoma (where E-cadherin is frequently mutate

114 he high ER mRNA group, 5 (18%) were invasive lobular carcinomas whereas all 24 tumors with low ER mRN

115 ptions are becoming widely used for invasive lobular carcinoma, yielding outcomes equivalent to those